Kymera Appoints Penny Carlson as SVP Development Operations; COO to Retire
KYMR•Kymera Therapeutics has appointed Penny Carlson as Senior Vice President, Development Operations, where she will oversee global clinical development operations for its oral immunology portfolio. Chief Operating Officer Jeremy Chadwick will retire and transition into an advisory role through the end of 2026.
1. Executive Leadership Changes
Kymera Therapeutics announced that Penny Carlson has joined as Senior Vice President, Development Operations to lead global clinical trial execution for its oral immunology portfolio. Jeremy Chadwick will step down as Chief Operating Officer and serve as an advisor through December 2026.
2. Carlson's Experience
Carlson brings over 20 years of biopharmaceutical leadership, having led global clinical development operations at Takeda and held senior roles at Millennium Pharmaceuticals and Aileron Therapeutics. Her expertise spans clinical program management, study execution and data management across multiple therapeutic areas.
3. Pipeline and Operational Impact
In her new role, Carlson will guide mid- and late-stage trials as Kymera advances its targeted protein degradation candidates toward commercialization. Her appointment aligns with the company’s strategy to accelerate its oral small molecule degrader pipeline for immunological diseases.
